ELDN
Eledon Pharmaceuticals Inc (ELDN)
Healthcare • NASDAQ • $3.88+0.52%
- Symbol
- ELDN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $3.88
- Daily Change
- +0.52%
- Market Cap
- $299.49M
- Trailing P/E
- N/A
- Forward P/E
- -4.83
- 52W High
- $4.60
- 52W Low
- $1.35
- Analyst Target
- $8.00
- Dividend Yield
- N/A
- Beta
- 0.95
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Nov…
Company websiteResearch ELDN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.